ClinicalTrials.gg
CompletedNCT03429049Updated Jul 26, 2022Results posted

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

A Phase 3 interventional study of CNTX-4975-05 and Placebo in Osteoarthritis, Knee, sponsored by Centrexion Therapeutics. Completed at 33 sites in United States. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-07-26.

Sponsored by Centrexion Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
40 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
100th of 691
332 · median 72
Started
2018
with 54 others
Phase 3
76 of 796
6 open now
Registered
387th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 100th largest by enrollment of the 691 interventional ones that give a count, is one of 55 that started in 2018, is one of 76 in phase 3, and was the 387th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, randomized, double-blind, placebo-controlled, single injection, 52-week study to evaluate the analgesic efficacy and safety of a single intra-articular (IA) CNTX-4975-05 (capsaicin), compared to IA placebo, in subjects with chronic, moderate-to-severe osteoarthritis (OA) knee pain.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • analgesic
  • non-opioid
  • capsaicin
  • intra-articular
  • osteoarthritis
  • pain
  • knee pain
04

Who can participate

Ages eligible
40 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female subjects between 40 and 95 years of age (inclusive) at the time of the Screening Visit with the ability to comply with answering the electronic diary using the study-provided tablet computers.
  • Confirmation of osteoarthritis (OA) of the knee.
  • Confirmation of OA of the index knee.
  • Moderate to severe pain in the index knee associated with OA must be stable for a minimum of 6 months prior to Screening, as assessed by the investigator.
  • ≤45 kg/m\^2.
  • Must have failed 2 or more prior therapies.
  • Females not of , defined as for at least 1 year, or surgically sterile, or practicing one of the following medically acceptable methods of throughout the study period.
  • Subject agrees to stay on their current pain medication (including over the counter (OTC) medications) from the time of Screening through Week 12. The current pain medication must be taken only for pain in the index knee, and not for another pain indication.
  • Subject agrees to take only the allowed rescue medications for OA knee pain of the index knee from the time of Screening through study completion and agrees to use no topical medications for OA knee pain during the trial.

Key Exclusion Criteria:

  • Joint replacement surgery of the index knee at any time, or open surgery of the index knee in the past 24 months.
  • Prior arthroscopic surgery of the index knee within 6 months of Screening.
  • Any painful conditions of the index knee due to joint disease other than OA.
  • Periarticular pain from any cause.
  • Pain in the non-index knee that is >3 on a numeric pain rating scale (NPRS) (0-10) when walking or at rest.
  • Other chronic pain anywhere in the body that requires the use of analgesic medications.
  • Instability of the index knee.
  • Misalignment (>10 degrees varus or valgus) of the index knee on standing.
  • Documented history of neuropathic arthropathy or finding of bony fragmentation in the index knee with imaging.
  • Physical/ occupational/ chiropractic therapy for the lower extremities or acupuncture for the lower extremities within 30 days of Screening, or need for such therapy during the study.
  • Plans to have surgery, other invasive procedures, or IA injections while participating in the study.
  • Has used topical capsaicin on the index knee within 90 days of Screening.
  • Current use of opioids for any condition other than for OA of the index knee.
  • injection into the index knee within 90 days of Screening.
  • Received IA viscosupplementation (eg, Synvisc®, Hyalgan®) within 90 days of Screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo of 2.0 mL for IA injection

    Drug: Placebo

  • Experimental
    CNTX-4975-05

    Pre-filled glass syringes administered as a single 2.0 mL IA injection

    Drug: CNTX-4975-05

Interventions

  • Receiving CNTX-4975-05 injection

  • DrugPlacebo

    Receiving Placebo injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee

    Average daily OA pain in the index knee while walking was evaluated using a 0 to 10 Numerical Pain Rating Scale (NPRS) (0 = no pain and 10 = worst possible pain). 0 was the best score and 10 was the worst score. Subjects used an ePRO at bedtime (9:00 PM ± 3 hours) to record on a daily basis their average daily OA knee pain score with walking during the previous 24 hours.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Mean Change From Baseline in WOMAC A (Pain) Dimension Total Score

    The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The pain dimension includes 5 items about the amount of pain experienced doing various activities (walking, stair climbing, nocturnal, at rest, weight bearing). The score ranges from 0 to 50.

    Time frame: Baseline, Week 12

  2. Mean Change From Baseline WOMAC B (Stiffness) Dimension Total Score

    The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The stiffness dimension has 2 items: joint stiffness upon wakening and joint stiffness later in the day. The score ranges from 0 to 20.

    Time frame: Baseline, Week 12

  3. Mean Change From Baseline in WOMAC C (Physical Function) Dimension Total Score

    The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The function dimension asks about the degree of difficulty in doing 17 activities due to the reference joint. The score ranges from 0 to 170.

    Time frame: Baseline, Week 12

07

Results

Posted Apr 8, 2022

Participant flow

Participant flow — Overall Study
MilestonePlaceboCNTX-4975-05
Started138194
Treated136189
Completed110152
Not completed2842
Withdrew: Adverse event23
Withdrew: Death01
Withdrew: Lack of efficacy42
Withdrew: Lost to follow-up98
Withdrew: Physician decision10
Withdrew: Protocol violation30
Withdrew: Sponsor decision20
Withdrew: Withdrawal by subject420
Withdrew: Other reasons: unable to administer ip, collect aspirate38

Outcome measures

PrimaryChange From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee

Average daily OA pain in the index knee while walking was evaluated using a 0 to 10 Numerical Pain Rating Scale (NPRS) (0 = no pain and 10 = worst possible pain). 0 was the best score and 10 was the worst score. Subjects used an ePRO at bedtime (9:00 PM ± 3 hours) to record on a daily basis their average daily OA knee pain score with walking during the previous 24 hours.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee
score on a scalePlaceboCNTX-4975-05
Change From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee-2.84 ± 0.212-3.17 ± 0.182
Statistical analysis
  • Placebo vs CNTX-4975-05 · Mixed Models Analysis · p = 0.1904 · Least squares mean difference: -0.33 · 95% CI -0.84 to 0.17
SecondaryMean Change From Baseline in WOMAC A (Pain) Dimension Total Score

The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The pain dimension includes 5 items about the amount of pain experienced doing various activities (walking, stair climbing, nocturnal, at rest, weight bearing). The score ranges from 0 to 50.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in WOMAC A (Pain) Dimension Total Score
score on a scalePlaceboCNTX-4975-05
Mean Change From Baseline in WOMAC A (Pain) Dimension Total Score-12.72 ± 1.002-15.42 ± 0.860
Statistical analysis
  • Placebo vs CNTX-4975-05 · Mixed Models Analysis · p = 0.0257 · Mean difference (final values): -2.70 · 95% CI -5.07 to -0.33
SecondaryMean Change From Baseline WOMAC B (Stiffness) Dimension Total Score

The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The stiffness dimension has 2 items: joint stiffness upon wakening and joint stiffness later in the day. The score ranges from 0 to 20.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline WOMAC B (Stiffness) Dimension Total Score
score on a scalePlaceboCNTX-4975-05
Mean Change From Baseline WOMAC B (Stiffness) Dimension Total Score-5.21 ± 0.448-6.15 ± 0.386
Statistical analysis
  • Placebo vs CNTX-4975-05 · Mixed Models Analysis · p = 0.0855 · Least squares mean difference: -0.94 · 95% CI -2.01 to 0.13
SecondaryMean Change From Baseline in WOMAC C (Physical Function) Dimension Total Score

The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The function dimension asks about the degree of difficulty in doing 17 activities due to the reference joint. The score ranges from 0 to 170.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in WOMAC C (Physical Function) Dimension Total Score
score on a scalePlaceboCNTX-4975-05
Mean Change From Baseline in WOMAC C (Physical Function) Dimension Total Score-42.70 ± 3.417-50.49 ± 2.935
Statistical analysis
  • Placebo vs CNTX-4975-05 · Mixed Models Analysis · p = 0.0550 · Mean difference (final values): -7.80 · 95% CI -15.86 to 0.26

Adverse events

Collected over 1 Year. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/136 (0%)6/136 (4.4%)45/136 (33.1%)
CNTX-4975-051/189 (0.5%)6/189 (3.2%)110/189 (58.2%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlaceboCNTX-4975-05
Foot FractureInjury, poisoning and procedural complications1/1360/189
Hip FractureInjury, poisoning and procedural complications1/1360/189
Chest PainGeneral disorders1/1360/189
Oestrogen receipt positive breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1360/189
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1360/189
Peripheral IschaemiaVascular disorders1/1360/189
Vertigo PositionalEar and labyrinth disorders1/1360/189
Hip ArthroplastySurgical and medical procedures1/1360/189
Acetabulum FractureInjury, poisoning and procedural complications0/1361/189
Craniocerebral InjuryInjury, poisoning and procedural complications0/1361/189
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboCNTX-4975-05
ArthralgiaMusculoskeletal and connective tissue disorders6/13619/189
NauseaGastrointestinal disorders2/13612/189
Upper respiratory tract infectionInfections and infestations7/1368/189
OsteoarthritisMusculoskeletal and connective tissue disorders3/1368/189
DizzinessNervous system disorders3/1366/189
HyperhidrosisSkin and subcutaneous tissue disorders0/1366/189
Back painMusculoskeletal and connective tissue disorders2/1365/189
Joint effusionMusculoskeletal and connective tissue disorders1/1365/189
InfluenzaInfections and infestations1/1365/189
Procedural painInjury, poisoning and procedural complications2/1365/189

Baseline characteristics

The safety population is defined as any subject that received any amount of investigational product

Age, Continuous
Age, Continuous(Years)PlaceboCNTX-4975-05Total
Mean61.8 ± 9.561.8 ± 9.161.8 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCNTX-4975-05Total
Female83123206
Male5366119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCNTX-4975-05Total
Hispanic or Latino233760
Not Hispanic or Latino113152265
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCNTX-4975-05Total
American Indian or Alaska Native101
Asian121527
Native Hawaiian or Other Pacific Islander000
Black or African American304676
White90123213
More than one race011
Unknown or Not Reported347
Body Mass Index
Body Mass Index(kg/m^2)PlaceboCNTX-4975-05Total
Mean32.07 ± 5.80131.55 ± 5.69231.77 ± 5.734
Baseline Pain with Walking NPRS (0-10) Score
Baseline Pain with Walking NPRS (0-10) Score(score on a scale)PlaceboCNTX-4975-05Total
Mean7.09 ± 1.1527.06 ± 1.0827.07 ± 1.110
Baseline WOMAC A (Pain) Domain Score (range 0-50)
Baseline WOMAC A (Pain) Domain Score (range 0-50)(score on a scale)PlaceboCNTX-4975-05Total
Mean30.80 ± 8.16631.92 ± 7.49331.45 ± 7.788
Baseline WOMAC B (Stiffness) Domain Score (range 0-20)
Baseline WOMAC B (Stiffness) Domain Score (range 0-20)(score on a scale)PlaceboCNTX-4975-05Total
Mean13.24 ± 3.38913.28 ± 3.23213.26 ± 3.293

1 further baseline measures are reported on the registry.

08

Study locations

33 sites
  • Alabama Orthopaedic Center - Research
    Birmingham, Alabama 35209, United States
  • Cahaba Research, Inc
    Birmingham, Alabama 35242, United States
  • Coastal Clinical Research, Inc
    Mobile, Alabama 36608, United States
  • Noble Clinical Research, LLC
    Tucson, Arizona 85704, United States
  • Orange County Research Institute
    Anaheim, California 92801, United States
  • Core Healthcare Group
    Cerritos, California 90703, United States
  • Biosolutions Clinical Research Center
    La Mesa, California 91942, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Tampa Bay Medical Research, Inc
    Clearwater, Florida 33761, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • M&M Medical Center, Inc
    Miami, Florida 33185, United States
  • Sensible Healthcare, LLC
    Ocoee, Florida 34761, United States
  • Jewett Orthopaedic
    Orlando, Florida 32822, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • Drug Studies America
    Marietta, Georgia 30060, United States
  • Georgia Institute for Clinical Research, LLC
    Marietta, Georgia 30060, United States
  • Atlanta Orthopaedic Institute, LLC
    Stockbridge, Georgia 30281, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Mid America PolyClinic
    Overland Park, Kansas 66210, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Tristan Medical Enterprises PC, dba
    North Attleboro, Massachusetts 02760, United States
  • Medical Research Associates, Inc
    Traverse City, Michigan 49686, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Bone Joint & Spine Surgeons, Inc
    Toledo, Ohio 43623, United States
  • Tekton Research, Inc
    Austin, Texas 78745, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Clinical Investigations of Texas
    Plano, Texas 75075, United States
  • Ortho Virginia
    Arlington, Virginia 22205, United States
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Nov 2019, 21 months.

Results were first posted in Apr 2022, 2 years 4 months after primary completion.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 21 months is close to that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2018
First posted
Feb 12, 2018
StartActual
Jan 24, 2018
Primary completionActual
Nov 22, 2019
CompletionActual
Nov 22, 2019
Results first posted
Apr 8, 2022
Last update
Jul 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03429049
Lead sponsor
Centrexion Therapeutics
Responsible party
Sponsor
First posted
Feb 12, 2018
Start date
Jan 24, 2018
Primary completion
Nov 22, 2019
Completion
Nov 22, 2019
Results posted
Apr 8, 2022
Last update
Jul 26, 2022

Study contacts

Randall M. Stevens, MD
study chair · Centrexion Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CNTX-4975-05

Start the discussion